【Tai-Tsung】Board of Directors Approves 115 Second Quarter Financial Report
Tai-Tsung's Board of Directors approved the 115 second quarter financial report on August 11, 115. C… · 2026-08-11
泰宗 News Releases
Tai Tsung Announces Board Meeting Scheduled for August 11, 115 to Review 2nd Quarter Financial Report
Tai Tsung announced that the board meeting to review the financial report for the second quarter of … · 2026-08-03
Tai-Chung Announces Positive Interim Analysis Results from Phase III Clinical Trial of U101 for Recurrent UTI Prevention
Tai-Chung Biotech Co., Ltd. (stock code: 4169) announced that the interim analysis of its Phase III … · 2026-07-23
Tai Tsung Announces Interim Analysis Results of Phase III Clinical Trial for U101, a Novel Drug for Preventing Recurrent Urinary Tract Infections (rUTI)
Tai Tsung announces the completion of the interim analysis of the Phase III clinical trial for U101,… · 2026-07-23
Tai Tsung Announces Trading Halt Starting July 23, 2026, Following Exchange Approval to Disclose Material Information
Tai Tsung has announced a temporary suspension of trading effective July 23, 2026, approved by the T… · 2026-07-22
Tai Tsung Announces Financial Information Due to Securities Trading Alert on Taiwan Stock Exchange
Tai Tsung discloses financial results after reaching the Taiwan Stock Exchange's threshold for tradi… · 2026-07-08
Tai-Tsung Biotech Board Resolves to Waive Subscription Rights in Cash Increase of Subsidiary Taiwan Gene Nucleic Acid New Drug Co., Ltd.
Tai-Tsung Biotechnology Co., Ltd. has resolved at its board meeting to waive its subscription rights… · 2026-07-02
Tai Tsung Announces Board Approval of Exclusive Licensing Agreement with Subsidiary TCM Life Science Inc. for U101
Tai Tsung's board has approved an exclusive licensing agreement with its U.S.-based subsidiary TCM L… · 2026-07-02
Tai Tsung Announces Members and Convener of the 6th Compensation and Nomination Committee
Tai Tsung has announced the appointment of members and convener for its 6th Compensation and Nominat… · 2026-07-02
Tai-Chong Announces Board Appointment of Second-Term Sustainability Committee Members
On July 2, 2026 (115/07/02), Tai-Chong's Board appointed the second-term members of the Sustainabili… · 2026-07-02
Tai Tsung Announces Adjustment to Cash Dividend Payout Rate
Tai Tsung has announced a revision to its cash dividend per share from NT$0.36 to NT$0.31999074 due … · 2026-07-02
Tai-Chong Announces Board Approval of Exclusive Licensing Agreement with Subsidiary TCM Life Science Inc. for U101
Tai-Chong's Board of Directors has approved an exclusive licensing agreement with its U.S. subsidiar… · 2026-07-02
Tai Tsung Announces Cash Dividend Ex-Dividend Date
Tai Tsung has announced adjustments to its cash dividend due to a capital increase, revising the per… · 2026-07-02
Tai Tsung Invited to Participate in Corporate Briefing Hosted by Yuanta Securities to Present Business Overview
Tai Tsung has been invited to attend the corporate briefing hosted by Yuanta Securities to present a… · 2026-06-19
Taizong Biotech: Announcement Regarding Termination of OTC Trading and Listing on Taiwan Stock Exchange
Taizong Biotech announced that its stock will terminate OTC trading and be listed on the Taiwan Stoc… · 2026-04-07
Taizong Biotech: Announcement Regarding Termination of OTC Trading and Listing on Taiwan Stock Exchange
Taizong Biotech announced that its stock will terminate OTC trading and be listed on the Taiwan Stoc… · 2026-04-07
[Biotegy] Results of stabilization operations for the first five trading days following the company's listing
Biotegy announced that during its first five days of listing, the underwriter purchased 0 shares for… · 2026-04-16
[TaiGen] Announcement of Election Results for the Board of Directors at the 2026 Annual General Shareholders' Meeting
TaiGen Biotechnology held its Annual General Shareholders' Meeting on June 5, 2026, to conduct a ful… · 2026-06-05
[TaiGen] Announcement of the 4th Audit Committee Members and Convener
TaiGen Biotechnology announced that the members and convener of its 4th Audit Committee—Kuo Cheng-hu… · 2026-06-05
[Apex] Announcement regarding the expiration of the term of the 1st Sustainability Committee
Apex Medical Corp announced that the term of its 1st Sustainability Committee has expired in conjunc… · 2026-06-05
[TCM] Resolution on Lifting Non-Compete Restrictions for Directors at the 2026 Annual General Shareholders' Meeting
TCM Biotech announced that at its 2026 Annual General Shareholders' Meeting held on June 5, it passe… · 2026-06-05
[Tai Zong] Announcement of Important Resolutions of the 2026 Annual General Meeting of Shareholders
Tai Zong held its Annual General Meeting on June 5, 2026, approving the earnings distribution for th… · 2026-06-05
[TaiGen] Announcement on Board Selection of Chairman (Re-election)
TaiGen Biotechnology announced that the board of directors selected Xu Huanqing to continue as Chair… · 2026-06-05
[TaiGen] Announcement regarding the expiration of the term of the 5th Compensation and Nomination Committee members
TaiGen Biotechnology announced that, due to the expiration of the Board of Directors' term, the term… · 2026-06-05
Tai Tsung Reports May 2026 Revenue of NT$57.163 Million (YoY -17.2%)
Tai Tsung (stock code: 4169), a biotechnology and healthcare company, announced its revenue for May … · 2026-05-01
【Tsai Tsung】 (Supplementary Announcement) Notice of Board Meeting to Submit the Financial Report for the First Quarter of 115
Tsai Tsung Company issued a supplementary announcement notifying that the financial report for the f… · 2026-06-08
Taizong Biotech: Announcement Regarding Termination of OTC Trading and Listing on Taiwan Stock Exchange
Taizong Biotech announced that its stock will terminate OTC trading and be listed on the Taiwan Stoc… · 2026-04-07
Tai-Tsung Corp. March 2026 Revenue NT$62 million (YoY +9.1%)
Tai-Tsung's monthly revenue for March 2026 was NT$62 million, an increase of 9.1% year-over-year. Th… · 2026-03-01
【Taixong】April 2026 Revenue 59.14 Million NTD (Year-on-Year +15.4%)
Taixong (4169), a biotechnology and medical company, reported April 2026 revenue of 59.14 million NT… · 2026-04-01
[Tai Tsung] Announcement of the Company's Subscription to Private Placement Ordinary Shares of Xiangyi Pharmaceutical Co., Ltd.
Tai Tsung announced its plan to strategically invest in Xiangyi Pharmaceutical by subscribing to 20 … · 2026-05-07
【TaiGen】The Company's Board of Directors Resolves to Approve the 2026 Q1 Consolidated Financial Report
TaiGen Biotechnology announced that its Board of Directors approved the 2026 Q1 consolidated financi… · 2026-05-07
【TaiGen】The Company's Board of Directors Resolves to Waive Non-Compete Restrictions for Managers
TaiGen announced that its Board of Directors approved waiving non-compete restrictions for Chairman … · 2026-05-07
[Biotegy] Results of stabilization operations for the first five trading days following the company's listing
Biotegy announced that during its first five days of listing, the underwriter purchased 0 shares for… · 2026-04-16
Tai-Tsung Corp. March 2026 Revenue NT$62 million (YoY +9.1%)
Tai-Tsung's monthly revenue for March 2026 was NT$62 million, an increase of 9.1% year-over-year. Th… · 2026-03-01
【Taixong】April 2026 Revenue 59.14 Million NTD (Year-on-Year +15.4%)
Taixong (4169), a biotechnology and medical company, reported April 2026 revenue of 59.14 million NT… · 2026-04-01
Taisun Biotech Corrects Errors in Its Q1 2026 Consolidated Financial Report
On May 20, 2026, Taisun Biotechnology Co., Ltd. announced a correction to its Q1 2026 consolidated f… · 2026-05-20
【TaiGen】The Company's Board of Directors Resolves to Approve the 2026 Q1 Consolidated Financial Report
TaiGen Biotechnology announced that its Board of Directors approved the 2026 Q1 consolidated financi… · 2026-05-07
【TaiGen】The Company's Board of Directors Resolves to Waive Non-Compete Restrictions for Managers
TaiGen announced that its Board of Directors approved waiving non-compete restrictions for Chairman … · 2026-05-07
[Tai Tsung] Announcement of the Company's Subscription to Private Placement Ordinary Shares of Xiangyi Pharmaceutical Co., Ltd.
Tai Tsung announced its plan to strategically invest in Xiangyi Pharmaceutical by subscribing to 20 … · 2026-05-07